Emerging from hepatitis B flops, Assembly Bio showcases early data on next-gen drugs

John McHutchison will be leaving Assembly Biosciences with a glimpse at the future he promised is in tow after the biotech ran into multiple setbacks in its pursuit of a functional cure for hepatitis B.